Davis et al.,(27) analyzed a biomarker panel (estrogen receptor, HER-2, Ki67, p53, cyclin D1, COX-2, caveolin-1, survivin, and PPAR-g) and a DCIS clinical and histological factor panel to determine associations with recurrence of disease. Here, BIRC5 is linked to ductal breast carcinoma in situ.